fasudil has been researched along with Osteosarcoma in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Xia, Y | 1 |
Cai, X | 1 |
Fan, J | 1 |
Zhang, L | 1 |
Li, Z | 1 |
Ren, J | 1 |
Wu, G | 1 |
Zhu, F | 1 |
1 other study available for fasudil and Osteosarcoma
Article | Year |
---|---|
RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2017 |